Does the media refer more to BNTX or RYTM?

In the previous week, BioNTech had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 20 mentions for BioNTech and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat BioNTech's score of -0.10 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RYTM or INSM?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Insmed. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 7 mentions for Insmed. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Insmed's score of 0.90 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or RYTM?

In the previous week, Roivant Sciences had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 21 mentions for Roivant Sciences and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Roivant Sciences' score of 0.74 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RYTM or INCY?

In the previous week, Incyte had 25 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 40 mentions for Incyte and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Incyte's score of 1.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 31 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer RYTM or UTHR?

In the previous week, United Therapeutics had 28 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 43 mentions for United Therapeutics and 15 mentions for Rhythm Pharmaceuticals. United Therapeutics' average media sentiment score of 1.47 beat Rhythm Pharmaceuticals' score of 1.42 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 34 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rhythm Pharmaceuticals (RYTM) Competitors

$107.17 -5.36 (-4.76%)

As of 08/28/2026 04:00 PM Eastern

Compare

RYTM vs. BNTX, INSM, ROIV, INCY, and UTHR

Should you buy Rhythm Pharmaceuticals stock or one of its competitors? Rhythm Pharmaceuticals's main competitors and comparable companies include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Incyte (INCY), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rhythm Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

BioNTech has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Rhythm Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A

In the previous week, BioNTech had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 20 mentions for BioNTech and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat BioNTech's score of -0.10 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech currently has a consensus target price of $127.81, suggesting a potential upside of 25.22%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 31.68%. Given Rhythm Pharmaceuticals' higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioNTech has a net margin of -63.54% compared to Rhythm Pharmaceuticals' net margin of -85.59%. BioNTech's return on equity of -6.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Summary

BioNTech beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Insmed?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Rhythm Pharmaceuticals has higher earnings, but lower revenue than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
Insmed	$606.42M	42.69	-$1.28B	-$4.11	N/A

Insmed has a net margin of -76.94% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Insmed's return on equity of -123.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Insmed	-76.94%	-123.94%	-44.30%

Rhythm Pharmaceuticals currently has a consensus price target of $141.12, indicating a potential upside of 31.68%. Insmed has a consensus price target of $205.52, indicating a potential upside of 73.38%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Insmed. MarketBeat recorded 15 mentions for Rhythm Pharmaceuticals and 7 mentions for Insmed. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Insmed's score of 0.90 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

Insmed beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Roivant Sciences presently has a consensus price target of $35.14, indicating a potential upside of 1.23%. Rhythm Pharmaceuticals has a consensus price target of $141.12, indicating a potential upside of 31.68%. Given Rhythm Pharmaceuticals' higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

In the previous week, Roivant Sciences had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 21 mentions for Roivant Sciences and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Roivant Sciences' score of 0.74 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,035.32	-$299.77M	-$0.53	N/A
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A

Summary

Roivant Sciences beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Incyte?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

In the previous week, Incyte had 25 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 40 mentions for Incyte and 15 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Incyte's score of 1.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	31 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

97.0% of Incyte shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Incyte has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Incyte has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
Incyte	$5.14B	4.90	$1.29B	$7.85	15.84

Incyte has a net margin of 27.71% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Incyte's return on equity of 29.93% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Incyte	27.71%	29.93%	22.88%

Rhythm Pharmaceuticals currently has a consensus target price of $141.12, indicating a potential upside of 31.68%. Incyte has a consensus target price of $123.10, indicating a potential downside of 1.02%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Incyte beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to United Therapeutics?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

United Therapeutics has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A
United Therapeutics	$3.18B	6.95	$1.33B	$27.95	18.44

94.1% of United Therapeutics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Rhythm Pharmaceuticals' net margin of -85.59%. United Therapeutics' return on equity of 20.18% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, United Therapeutics had 28 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 43 mentions for United Therapeutics and 15 mentions for Rhythm Pharmaceuticals. United Therapeutics' average media sentiment score of 1.47 beat Rhythm Pharmaceuticals' score of 1.42 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	34 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals currently has a consensus price target of $141.12, suggesting a potential upside of 31.68%. United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 25.32%. Given Rhythm Pharmaceuticals' higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Rhythm Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYTM vs. The Competition

Export

Metric	Rhythm Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.34B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-34.46	11.62	273.16	25.45
Price / Sales	30.61	1,315.05	614.81	86.98
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	71.45	16.53	12.98	6.14
Net Income	-$196.54M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-2.57%	-0.31%	0.13%	-0.80%
1 Month Performance	1.35%	9.80%	7.08%	4.13%
1 Year Performance	3.90%	55.66%	24.67%	15.17%

Rhythm Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYTM Rhythm Pharmaceuticals	2.874 of 5 stars	$107.17 -4.8%	$141.12 +31.7%	+3.9%	$7.34B	$239.92M	N/A	140	Positive News Analyst Forecast Gap Down
BNTX BioNTech	3.29 of 5 stars	$112.82 -3.2%	$127.81 +13.3%	+2.1%	$29.48B	$3.25B	N/A	7,807	Trending News Options Volume Gap Down
INSM Insmed	3.3825 of 5 stars	$123.98 -1.4%	$205.52 +65.8%	-12.9%	$27.47B	$1.14B	N/A	1,664
ROIV Roivant Sciences	2.0218 of 5 stars	$36.36 +0.2%	$35.14 -3.4%	+190.9%	$26.22B	$7.53M	N/A	860	Trending News Analyst Forecast
INCY Incyte	3.6811 of 5 stars	$127.98 +0.1%	$123.10 -3.8%	+47.0%	$25.91B	$5.14B	16.30	2,844	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYTM) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. BNTX, INSM, ROIV, INCY, and UTHR

How does Rhythm Pharmaceuticals compare to BioNTech?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Summary

How does Rhythm Pharmaceuticals compare to Incyte?

Summary

How does Rhythm Pharmaceuticals compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. BNTX, INSM, ROIV, INCY, and UTHR

How does Rhythm Pharmaceuticals compare to BioNTech?

Which has more volatility & risk, BNTX or RYTM?

Which has preferable earnings and valuation, BNTX or RYTM?

Does the media refer more to BNTX or RYTM?

Do analysts recommend BNTX or RYTM?

Do insiders and institutionals hold more shares of BNTX or RYTM?

Is BNTX or RYTM more profitable?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Which has higher valuation and earnings, RYTM or INSM?

Is RYTM or INSM more profitable?

Do analysts recommend RYTM or INSM?

Does the media favor RYTM or INSM?

Which has more risk & volatility, RYTM or INSM?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Do analysts rate ROIV or RYTM?

Is ROIV or RYTM more profitable?

Which has more risk and volatility, ROIV or RYTM?

Does the media refer more to ROIV or RYTM?

Do insiders and institutionals believe in ROIV or RYTM?

Which has better valuation & earnings, ROIV or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Incyte?

Does the media favor RYTM or INCY?

Do insiders and institutionals have more ownership in RYTM or INCY?

Which has more risk and volatility, RYTM or INCY?

Which has higher valuation & earnings, RYTM or INCY?

Is RYTM or INCY more profitable?

Do analysts rate RYTM or INCY?

Summary

How does Rhythm Pharmaceuticals compare to United Therapeutics?

Which has preferable valuation & earnings, RYTM or UTHR?

Do institutionals & insiders hold more shares of RYTM or UTHR?

Which has more risk and volatility, RYTM or UTHR?

Is RYTM or UTHR more profitable?

Does the media prefer RYTM or UTHR?

Do analysts rate RYTM or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools